Peregrine Pharmaceuticals Reports Positive Phase Ib Results For Its Targeted Immunotherapy Bavituximab In Chronic Hepatitis C Infection

Thu, 15 Feb 2007 02:00 PM EST

... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today reported preliminary top-line results from a Phase lb study of its targeted immunotherapy bavituximab in patients with chronic HCV infection. [click link for full article] ...